



Advances in Cancer Immunology and Immunotherapy

Guest Editors:

Dr. Wenjie Jin

Institute for Translational
Bioengineering, F. Hoffmann-La
Roche Grenzacherstrasse 124,
4070 Basel, Switzerland

Dr. Zihe Huo

Departement Biomedizin,
University of Basel, DBM
Hebelstrasse - FG Guzman,
Hebelstrasse 20, 4031 Basel,
Switzerland

Deadline for manuscript
submissions:

closed (1 February 2024)

Message from the Guest Editors

Dear Colleagues,

Discuss recent discoveries in tumor immunology as well as immunotherapy and the insights of those discoveries for further therapies. You are welcome to contribute a novel report, observation, or review article that focuses on (i) recent discoveries in tumor immunology and immunotherapy, (ii) a mechanistic explanation of the limitations of current tumor studies and immunotherapy, (iii) how to translate current knowledge into further therapies, (iv) future directions of tumor immunology studies, and (v) novel techniques as well as models which can help future tumor immunology studies. Update the community on the latest progress in tumor immunology as well as immunotherapy and point out future directions for researchers.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: tumor immunology, immunotherapy, and novel tumor models.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com